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 Survival with end-stage renal disease 
(ESRD) is worse than with most cancers. 
Th e mortality rate of maintenance dialy-
sis patients is above 20 % per year, with 
more than half of the deaths related to 
cardiovascular complications. 1 A large 
number of biomarkers for mortality in 
ESRD have been published and include 
those associated with traditional cardio-
vascular risk factors, infl ammation, and 
protein-energy wasting (PEW). 2 Ghrelin 
is involved in the pathogenesis of all three 
of these pathways and may therefore be a 
very powerful biomarker for survival out-
comes in patients with ESRD ( Figure 1 ). 
Carrero and colleagues 3 (this issue) 
report that ESRD patients with infl am-
mation-associated PEW and low ghrelin 
and high leptin concentrations have the 
highest mortality risk. 
 Th ree distinct ghrelin gene products, 
namely, acyl ghrelin, des-acyl ghrelin, and 
obestatin, have been identified. Acyl 
 ghrelin is the endogenous cognate ligand 
for growth hormone secretagogue recep-
tor 1a (GHS-R1a) and constitutes only 
10 % of the circulating hormone. Des-acyl 
ghrelin, the non-acylated form, from 
alternative splicing of the ghrelin gene, is 
the major molecular form in the circula-
tion. Ghrelin  O -acyltransferase (GOAT), 
which acylates ghrelin at the serine-3 
position, is an important enzyme that 
controls the conversion of des-acyl to acyl 
ghrelin. Th e third ghrelin gene product, 
obestatin, is derived from the mammalian 
prepro-ghrelin gene by comparative 
genomic analysis. Acyl ghrelin is a circu-
lating hunger hormone and is considered 
the counterregulatory hormone for leptin. 
Des-acyl ghrelin has also been shown to 
actively participate in food intake. Des-
acyl ghrelin is secreted in a highly regu-
lated manner in response to food 
deprivation in mice. Intracerebroven-
tricular administration of rat des-acyl 
ghrelin to rats or mice stimulates feeding, 
but peripheral administration has no 
eff ect. Obestatin binds to an orphan G 
protein-coupled receptor, GPR39, to 
inhibit food intake by activating anorexi-
genic neurons in several brain regions. 
Thus, acyl ghrelin has orexigenic and 
des-acyl ghrelin and obestatin have 
 anorexigenic eff ects. It is important to 
assess the contribution of these diff erent 
counterregulatory circulating ghrelin pro-
teins as well as leptin in the consideration 
of weight regulation disorders. 4 
 Th e kidney degrades ghrelin. Increased 
total plasma ghrelin levels in ESRD 
are primarily due to the decreased degra-
dation of ghrelin in the kidney. Studies of 
circulating ghrelin in patients with ESRD 
have yielded inconsistent fi ndings due to 
several confounding factors. Th e tradi-
tional radioimmunoassay method meas-
ures the sum of both acylated and des-acyl 
ghrelin. More specifi c assays show that 
only plasma des-acyl ghrelin levels were 
elevated in ESRD patients. 5 Most studies 
do not account for obestatin. Likewise, the 
study of Carrero and colleagues 3 only 
measures total ghrelin by the traditional 
radioimmunoassay, and therefore its 
results have to be interpreted with these 
limitations in mind. Furthermore, it is 
important to assess ghrelin in the context 
of the nutritional status, since ghrelin par-
ticipates in weight and body composition 
regulation. Total skeletal muscle mass is a 
negative predictor of plasma ghrelin con-
centrations. Administration of a ghrelin 
mimetic signifi cantly increases fat-free 
mass. Elevated plasma ghrelin also cor-
relates with fat mass in ESRD patients. 4 
Th us, one would expect plasma acyl ghre-
lin, an orexigen and positive regulator of 
body and muscle mass, to be upregulated 
in anorexic and wasting conditions. PEW 
is prevalent in ESRD patients, and pres-
ence of normal to high plasma acyl ghrelin 
concentrations may represent ghrelin 
resistance, which could be due to elevated 
anorexigenic hormones such as leptin in 
the circulation. In this respect, the study 
by Carrero  et al. 3 provides important and 
novel information. Th e phenotype of PEW 
and high leptin and low ghrelin concen-
trations would represent a failure of ghre-
lin secretion to provide compensatory 
counterregulation, much like in the 
advanced type 2 diabetic patient with 
insulin resistance and decreased insulin 
secretion culminating in frank diabetes. 
 Ghrelin has signifi cant anti-infl amma-
tory eff ects. Treatment of rats aft er sub total 
nephrectomy reverses uremic cachexia 
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and, at the same time, causes a decrease in 
circulating infl ammatory cytokines, such 
as tumor necrosis factor and interleukin-6. 
Ghrelin-treated uremic animals also had 
a decrease in the expression of the inter-
leukin-1 receptor in the brainstem. 6 On 
the other hand, systemic infl ammation 
modulates ghrelin levels. Ghrelin levels fall 
in states of acute infl ammation such as 
bacterial lipopolysaccharide-induced 
cachexia, and the mechanism may involve 
the interleukin-1  receptor. Mice with 
genetic deletion of the interleukin-1  
receptor do not suppress  circulating ghre-
lin levels with lipopolysaccharide admin-
istration. Ghrelin concentrations are 
initially suppressed in experimental arthri-
tis as well as in patients with rheumatoid 
arthritis. Th is is followed by recovery of 
ghrelin concentrations, representing a 
compensatory mechanism to cachectic 
conditions. Th us it is important to assess 
the presence of systemic infl ammation 
when considering serum ghrelin as a 
biomarker of mortality in ESRD. Indeed, 
chronic infl ammation may have a stronger 
causal role in engendering atherosclerotic 
cardiovascular disease than traditional risk 
factors such as low-density lipoprotein 
hypercholesterolemia in ESRD. 
 Ghrelin receptors are widely expressed 
in the cardiovascular system. Ghrelin has 
benefi cial eff ects in various cardiovascular 
disease states. 7 Ghrelin improves cardiac 
contractility, reduces myocardial infarct 
size, and attenuates the reduction in 
left ventricular function induced by 
 experimental cardiac ischemia – reper-
fusion. Ghrelin has been shown to increase 
body weight, cardiac output, and diastolic 
thickness of the noninfarcted posterior 
wall, as well as to inhibit left  ventricular 
enlargement. In animal models of heart 
failure, ghrelin administration improves 
cardiac contractility and attenuates the 
development of cardiac cachexia. 8 In nor-
mal subjects, intravenous or subcutaneous 
ghrelin injection increases cardiac output, 
improves cardiac contractility, and causes 
a significant decrease in mean arterial 
pressure. Ghrelin has a therapeutic eff ect 
in patients with heart failure. It improves 
left  ventricular function, attenuates left  
ventricular and decreases systemic vascu-
lar resistances, and increases cardiac out-
put, cardiac index, and stroke volume 
index in patients with chronic heart fail-
ure. Ghrelin also increases body weight, 
lean body mass, and muscle strength in 
these patients. 9 Th ese results suggest that 
ghrelin could improve muscle wasting in 
patients with chronic heart failure and 
cardiac cachexia, a severe catabolic state 
similar to PEW in ESRD and resistant to 
long-term treatment with nutritional sup-
plements. In keeping with these fi ndings, 
other studies have emphasized that ghre-
lin might have a role in patients with end-
stage heart failure and cardiac cachexia, 
by improving cardiac function and 
increasing appetite. Intravenous adminis-
tration of ghrelin has therefore been pro-
posed as adjuvant therapy in heart failure, 
because of its beneficial effects on left 
 ventricular mass, left  ventricular ejection 
fraction, and left  ventricular end-systolic 
volume. 9 Ghrelin may also have a benefi -
cial eff ect on hypertension. A negative 
correlation has been noticed between 
ghrelin plasma levels and blood pressure. 
Ghrelin suppresses sympathetic activity 
and decreases blood pressure through 
mechanisms involving the central nervous 
system and sympathetic regulation. Ghre-
lin administration signifi cantly decreases 
plasma norepinephrine levels and the 
ratio of low- to high-frequency spectra of 
heart rate variability in rats with myocar-
dial infarction. Ghrelin infusion reduces 
peripheral resistance and blood pressure 
levels in humans, even though supraphys-
iological hormone levels are required to 
produce this effect. Ghrelin may also 
reduce blood pressure by vasodilation via 
eff ects on the endothelium and / or vascu-
lar smooth muscle cells. 7 Th us, ghrelin 
may have multiple benefi cial eff ects on the 
cardiovascular complications in ESRD. 
Assessment of cardiovascular risk factors 
such as blood pressure and left  ventricular 
mass and function as well as indices of 
congestive heart failure would have been 
very helpful in this consideration but was 
unfortunately not available in the study by 
Carrero  et al. 3 
 In summary, ghrelin has significant 
regulatory roles in energy homeostasis, 
systemic infl ammation, and the cardio-
vascular system. Th us, ghrelin is impor-
tant in the pathogenesis of PEW, systemic 
infl ammation, and cardiovascular compli-
cations in ESRD, all of which are signifi -
cantly associated with patient outcomes, 
including mortality. Plasma ghrelin may 
prove to be a powerful biomarker of mor-
tality in ESRD but should be best consid-
ered in the context of assay specifi city, 
other weight-regulating hormones, nutri-
tional status, systemic infl ammation, and 
cardiovascular risk factors. Ghrelin and its 
analogs have shown promise in improving 
anorexia in short-term studies in ESRD 
patients. Th e clinical utility of ghrelin will 
depend on long-term outcomes in revers-
ing PEW as well as improving morbidity 
and mortality. 10 ESRD patients with PEW, 
systemic infl ammation, and low ghrelin 
and high leptin concentrations have the 
highest mortality risk and may benefi t the 
most from ghrelin therapy. 
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 Figure 1  |  Ghrelin is a common factor in three different biomarker pathways that are 
associated with increased mortality in end-stage renal disease. 
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 Anti-neutrophil cytoplasmic  antibody 
(ANCA)-associated small-vessel vascu-
litides are predominantly diseases of older 
patients, frequently involving the kidney 
with focal necrotizing glomerulonephritis, 
and resulting in signifi cant morbidity and 
mortality. Th e majority of clinical trials 
investigating therapeutic regimens have 
recruited patients between 18 and 75 years 
old, leaving uncertainty regarding treat-
ment outcomes in those older patients for 
whom the risks of immunosuppressive 
treatment are frequently perceived to 
outweigh the benefits. Bomback and 
colleagues 1 (this issue) have performed 
a study to address disease outcome 
 specifi cally in very elderly patients (  >  80 
years old) with ANCA-associated renal 
disease. Th ey report that immunosuppres-
sion resulted in lower rates of end-stage 
renal disease (ESRD) at 1 year and lower 
morta lity at 2 years. So, on the basis of 
these data, should we be treating all our 
vasculitic patients with the same immuno-
suppressive protocols regardless of 
their age? 
 ANCA-associated vasculitis (AAV) 
constitutes a heterogeneous group of 
disorders with an incidence of around 
20 per million per year and a peak age of 
65 – 74 years. 2 In the elderly, AAV may 
present atypically or with vague constitu-
tional symptoms and can thus be diffi  cult 
to diagnose. A high index of clinical sus-
picion is required, evidenced by the fact 
that ANCA-associated pauci-immune 
glomerulonephritis is the most common 
fi nding in very elderly patients biopsied 
for acute kidney injury. 3 AAV may be life-
threatening, and, before the introduction 
of immunosuppressive treatment, morta-
lity was as high as 85 % at 1 year; this 
was radically transformed with the use of 
corticosteroids and alkylating agents. 4 
Even with modern treatment protocols, 
AAV results in considerable morbidity, 
with end-stage renal failure developing 
in 20 – 30 % of patients at 5 years, and 
significant mortality, with 18 and 24 % 
of patients dead by 1 and 5 years, respec-
tively. 5 Treatment is generally divided 
into more intensive induction therapy 
followed by long-term maintenance treat-
ment, but despite this, relapse rates are 
high, reaching almost 50 % over 5 years. 6 
 Treatment with immunosuppressive 
agents, such as cyclophosphamide and 
steroids, is associated with consider able 
side effects and cumulative toxicity, 
and a quarter of patients develop an 
adverse reaction during the fi rst year of 
treatment. 4 Little  et al. 7 have successfully 
teased out the relative importance of 
disease activity and treatment-related 
complications in contributing to early 
patient death. Prospective data from four 
European Vasculitis Study Group trials 
were used to compare the eff ects of vascu-
litis activity and adverse events on early 
mortality in 524 patients. One-year mor-
tality probability was 11.1 % , with 59 % 
of deaths attributable to adverse events 
